Cereno Scientific reports significant progress and a timeline adjustment in the Phase II study of CS1 in rare disease PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an update on the progress of the Phase II study of CS1 in pulmonary arterial hypertension (PAH). The company reports significant progress in the study, however, a slower recruitment pace than estimated during the last months and a longer start-up phase for two new clinics have affected the study timeline. The updated study timeline now expects study completion and top-line results during Q2 2024.The Phase II study of CS1 in the rare disease